Company / Accounts Receivable
Vanda Pharmaceuticals Inc. Accounts Receivable History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Accounts Receivable
$54.6M
FY2025
5-year range
$32.5M / $54.6M
FY2021-FY2025
Trend
+15.9%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Accounts Receivable has increased for 6 consecutive years, from $26M in FY2019 to $55M in FY2025.
Based on SEC 10-K filings.
$55M in FY2025 with a 5-year CAGR of +12.7%.
Improved from $34M to $55M over the past 2 years.
Accounts Receivable over time
Growth rates
- 3-Year CAGR
- +17.7%
- 5-Year CAGR
- +12.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- Vanda Pharmaceuticals Inc.'s accounts receivable has grown for 6 consecutive years.
- 5-year CAGR of +12.7%, indicating consistent growth.
- In FY2025, accounts receivable increased 15.9% year-over-year.
- Lowest accounts receivable in the period was in FY2017.
Company context
Key Data Points
- Altman Z-Score -3.96 (distress zone, below 1.8 threshold)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Accounts ReceivableValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $54.6M | +15.9% |
| FY2024 | $47.1M | +37.9% |
| FY2023 | $34.2M | +1.9% |
| FY2022 | $33.5M | +3.2% |
| FY2021 | $32.5M | +8.1% |
| FY2020 | $30.0M | +13.9% |
| FY2019 | $26.4M | -8.4% |
| FY2018 | $28.8M | +63.5% |
| FY2017 | $17.6M | -13.2% |
| FY2016 | $20.3M | +24.1% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026